Lupin Ltd., of Mumbai, India, appointed Kurt Nielsen president of Lupin-Somerset. Nielsen will be responsible for overall operations of the Gavis-Novel Somerset business and will be based out of Somerset, N.J. Read More

Jiangsu Hengrui Medicine Co. Ltd., of Lianyungang, China, said it entered a multiyear cancer research agreement with Albert Einstein College of Medicine to develop innovative cancer therapies. The immediate goal is to discover new targets and develop therapies in oncology space. Terms were not disclosed. Read More

HONG KONG – Dong-A ST. Co. Ltd., an 84-year-old South Korean pharmaceutical company, recently inked two separate licensing agreements with Nasdaq-listed Tobira Therapeutics Inc., as a further sign that Korean firms are reaching deeper into the global biopharma scene through licensing agreements with multinationals. Read More

HONG KONG — Elucidation of the molecular structure of nonstructural protein 1 (NS1) from the Zika virus by Chinese Academy of Sciences (CAS) researchers shows that NS1 is involved in viral pathogenesis, a finding that could lead to new diagnostic technologies and treatments, including for related pathogens such as dengue and West Nile viruses. Read More

SHANGHAI – Hua Medicine Ltd. has raised $50 million in a series C investment led by China-based Harvest Investments. Hua is now preparing a phase III trial for its lead candidate, HMS5552, a fourth generation glucokinase activator (GKA) for type 2 diabetes. Read More

TOKYO – In a world’s first, Japan-based Sanbio Inc. will conduct a phase II global trial into a treatment for chronic traumatic brain injury with allogeneic stem cells. Read More